Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

NCT03430687 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Investigators prefer to pursue other studies

Conditions

Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7
Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
Stage I Bladder Urothelial Carcinoma AJCC v6 and v7

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Talimogene Laherparepvec

Sponsor

University of California, San Francisco

Collaborators

[object Object]